<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00252499</url>
  </required_header>
  <id_info>
    <org_study_id>CDA-2-044-08S</org_study_id>
    <nct_id>NCT00252499</nct_id>
  </id_info>
  <brief_title>Insulin Resistance in Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>Insulin Resistance in Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is
      associated with altered peripheral and hepatic insulin sensitivity and to investigate
      potential mechanisms underlying insulin resistance in NAFLD by determining associations
      between hepatic and peripheral insulin sensitivity, hepatic steatosis, dyslipidemia,
      inflammatory cytokines, glucose metabolism, beta-cell function and body fat distribution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NAFLD and nonalcoholic steatohepatitis (NASH) are common liver disorders that are strongly
      associated with obesity, type 2 diabetes and dyslipidemia. The underlying pathophysiology of
      fatty infiltration of the liver is thought to be related to insulin resistance, which is an
      almost universal finding in patients with NAFLD. It is also possible that fat infiltration
      and inflammation in the liver may impair insulin sensitivity, either locally in the liver, or
      peripherally via the actions of inflammatory cytokines. We hypothesize that insulin
      resistance is a major causal factor leading to fat deposition in the liver and NAFLD, and
      thus interventions aimed at improving insulin sensitivity will result in a reduction of
      hepatic inflammation and steatosis.

      Specific Aim 1: To determine in a cross-sectional study whether NAFLD is associated with
      altered peripheral and hepatic insulin sensitivity and to study their relationships with
      hepatic steatosis, dyslipidemia, inflammatory cytokines, glucose metabolism, -cell function
      and body fat distribution. Specific Aim 2: To determine in a 6 month placebo-controlled
      double-blinded treatment study if treatment with rosiglitazone, an insulin sensitizer, or
      fenofibrate, a triglyceride lowering agent, will improve both hepatic as well as peripheral
      insulin sensitivity and thereby improve hepatic steatosis and inflammation in subjects with
      NAFLD.

      The results of the proposed study will have important implications for our understanding of
      the mechanisms underlying insulin resistance and abnormalities in lipid and glucose
      metabolism in subjects with NAFLD and for the design of future studies aimed at the
      prevention and treatment of this condition.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Protocol drug change required new clinicaltrails.gov entry
  </why_stopped>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver/Spleen Ratio at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Liver fat was estimated by non-contrast CT scan measuring the density ratio between the liver and spleen by Hounsfield units (liver/spleen ratio), which has been previously correlated with liver fat quantification by magnetic resonance spectroscopy.Ten separate measurements equally distributed throughout the liver and spleen were obtained and the Hounsfield units averaged. In subjects with more than one slice through the liver and spleen, the values for all slices were averaged.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Alanine Aminotransferase (ALT) Levels From Baseline to 6 Months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Liver Spleen Ratio by CT Scan From Baseline to 6 Months as a Measure of Fat in the Liver</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peripheral Insulin Sensitivity From Baseline to 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>A two-step stable isotope labeled, hyperinsulinemic-euglycemic clamp procedure was performed with a low dose insulin infusion (20 mU/m2/min) for 3 hours followed by a primed high dose insulin infusion (160 mU/m2/min x 5 minutes then 80 mU/m2/min) for two hours. D20 was infused and adjusted to maintain the blood glucose at 90 mg/dl. Samples for glucose, insulin and 6,6 2d glucose were drawn every 15 minutes during the final half hour of the basal, low dose and high dose insulin periods. Whole body insulin sensitivity was calculated as the rate of glucose disposal (Rd)/lean body mass during the high dose insulin infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Intra-abdominal Fat Area From Baseline to 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Unenhanced CT scan images were obtained on a General Electric Discovery HD750 CT scanner. Intra-abdominal (IAF) areas were measured at the top of the iliac crest and quantified using the Tomovision program (SliceOMatic V4.3) by one trained technologist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hepatic Insulin Sensitivity From Baseline to 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Hepatic insulin sensitivity was determined as the percent suppression of endogenous glucose production (EGP) at the end of the low dose insulin clamp.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Fatty Liver</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosiglitazone Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenofibrate Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone</intervention_name>
    <description>PPAR-gamma agonist, insulin sensitizer</description>
    <arm_group_label>Rosiglitazone Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
    <description>PPAR-alpha agonist, reduces triglycerides</description>
    <arm_group_label>Fenofibrate Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for rosiglitazone</intervention_name>
    <description>placebo tablets that are matched to look like rosiglitazone</description>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_label>Fenofibrate Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for fenofibrate</intervention_name>
    <description>placebo matched to look like fenofibrate tablets</description>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_label>Rosiglitazone Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80 years old Controls:

               -  otherwise healthy Case subjects: NAFLD on liver biopsy within the past 3 years or
                  presumed NAFLD with otherwise unexplained elevated ALT and fatty liver by CT or
                  ultrasound

          -  Able to comply with taking 3 pills a day for 6 months and follow-up safety visits

        Exclusion Criteria:

          -  Controls:

               -  history or evidence of hepatic steatosis

          -  Cases:

               -  Cirrhosis on liver biopsy or by clinical exam or fibrosis score

               -  Causes of liver dysfunction other than NASH

          -  Use of medications associated with hepatic steatosis:

               -  glucocorticoids

               -  estrogens

               -  tamoxifen

               -  amiodarone

               -  accutane

               -  sertraline

          -  Use of medications that cause insulin resistance:

               -  niacin

               -  glucocorticoids

               -  anti-HIV drugs or atypical antipsychotics

          -  Use of lipid-lowering medications except stable dose statin

          -  Use of anti-NASH drugs such as:

               -  ursodeoxycholic acid

               -  betaine milk thistle

          -  Use of coumadin

          -  Use of nitrates

          -  Significant alcohol consumption:

               -  Average &gt;20 grams/day

          -  In subjects with diabetes

               -  a HbA1c &gt;7.5% or use of insulin

               -  metformin

               -  rosiglitazone or pioglitazone

          -  Liver transaminases:

               -  Cases: ALT &gt;5x upper limit of normal

               -  Controls: ALT or AST above the normal range

          -  Iron saturation &gt;50%

          -  Creatinine &gt;1.5 mg/dl for men and &gt;1.4 mg/dl for women

          -  Hematocrit &lt;33%

          -  Pregnancy or lactation

          -  Significant weight loss within the past 6 months for controls, or since the liver
             biopsy for case subjects, history of significant coronary artery disease or congestive
             heart failure

          -  Retinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Marie Utzschneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound Health Care System, Seattle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System, Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/drgroup/</url>
    <description>Click here for more information about this study: Insulin resistance in non-alcoholic fatty liver disease</description>
  </link>
  <results_reference>
    <citation>Utzschneider KM, Largajolli A, Bertoldo A, Marcovina S, Nelson JE, Yeh MM, Kowdley KV, Kahn SE. Serum ferritin is associated with non-alcoholic fatty liver disease and decreased Β-cell function in non-diabetic men and women. J Diabetes Complications. 2014 Mar-Apr;28(2):177-84. doi: 10.1016/j.jdiacomp.2013.11.007. Epub 2013 Nov 26.</citation>
    <PMID>24360972</PMID>
  </results_reference>
  <results_reference>
    <citation>Kratz M, Marcovina S, Nelson JE, Yeh MM, Kowdley KV, Callahan HS, Song X, Di C, Utzschneider KM. Dairy fat intake is associated with glucose tolerance, hepatic and systemic insulin sensitivity, and liver fat but not β-cell function in humans. Am J Clin Nutr. 2014 Jun;99(6):1385-96. doi: 10.3945/ajcn.113.075457. Epub 2014 Apr 16.</citation>
    <PMID>24740208</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2005</study_first_submitted>
  <study_first_submitted_qc>November 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2005</study_first_posted>
  <results_first_submitted>November 12, 2013</results_first_submitted>
  <results_first_submitted_qc>March 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 11, 2014</results_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>beta cell function</keyword>
  <keyword>fenofibrate</keyword>
  <keyword>non-alcoholic steatohepatitis</keyword>
  <keyword>rosiglitazone</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited between 2006 and 2011 through referral from local gastroenterologists.</recruitment_details>
      <pre_assignment_details>Subjects underwent a screening visit prior to randomization to ensure that they qualified for the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd</description>
        </group>
        <group group_id="P3">
          <title>Arm 3</title>
          <description>micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd</description>
        </group>
        <group group_id="B3">
          <title>Arm 3</title>
          <description>micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" spread="7.3"/>
                    <measurement group_id="B2" value="56.5" spread="4.95"/>
                    <measurement group_id="B3" value="54.17" spread="5.08"/>
                    <measurement group_id="B4" value="52.6" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Liver/Spleen Ratio at 6 Months</title>
        <description>Liver fat was estimated by non-contrast CT scan measuring the density ratio between the liver and spleen by Hounsfield units (liver/spleen ratio), which has been previously correlated with liver fat quantification by magnetic resonance spectroscopy.Ten separate measurements equally distributed throughout the liver and spleen were obtained and the Hounsfield units averaged. In subjects with more than one slice through the liver and spleen, the values for all slices were averaged.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid</description>
          </group>
        </group_list>
        <measure>
          <title>Liver/Spleen Ratio at 6 Months</title>
          <description>Liver fat was estimated by non-contrast CT scan measuring the density ratio between the liver and spleen by Hounsfield units (liver/spleen ratio), which has been previously correlated with liver fat quantification by magnetic resonance spectroscopy.Ten separate measurements equally distributed throughout the liver and spleen were obtained and the Hounsfield units averaged. In subjects with more than one slice through the liver and spleen, the values for all slices were averaged.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.08"/>
                    <measurement group_id="O2" value="0.96" spread="0.25"/>
                    <measurement group_id="O3" value="0.60" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alanine Aminotransferase (ALT) Levels From Baseline to 6 Months</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alanine Aminotransferase (ALT) Levels From Baseline to 6 Months</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.5" spread="12.9"/>
                    <measurement group_id="O2" value="-35.0" spread="37.0"/>
                    <measurement group_id="O3" value="-15.2" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Liver Spleen Ratio by CT Scan From Baseline to 6 Months as a Measure of Fat in the Liver</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Liver Spleen Ratio by CT Scan From Baseline to 6 Months as a Measure of Fat in the Liver</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".09" spread=".10"/>
                    <measurement group_id="O2" value=".34" spread=".09"/>
                    <measurement group_id="O3" value="-.16" spread=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Peripheral Insulin Sensitivity From Baseline to 6 Months</title>
        <description>A two-step stable isotope labeled, hyperinsulinemic-euglycemic clamp procedure was performed with a low dose insulin infusion (20 mU/m2/min) for 3 hours followed by a primed high dose insulin infusion (160 mU/m2/min x 5 minutes then 80 mU/m2/min) for two hours. D20 was infused and adjusted to maintain the blood glucose at 90 mg/dl. Samples for glucose, insulin and 6,6 2d glucose were drawn every 15 minutes during the final half hour of the basal, low dose and high dose insulin periods. Whole body insulin sensitivity was calculated as the rate of glucose disposal (Rd)/lean body mass during the high dose insulin infusion.</description>
        <time_frame>6 months</time_frame>
        <population>One person in Arm 1 dropped out and thus is lacking 6 month data. The 6 month isotope data to calculate the rate of glucose disposal was not available for one subject in Arm 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Peripheral Insulin Sensitivity From Baseline to 6 Months</title>
          <description>A two-step stable isotope labeled, hyperinsulinemic-euglycemic clamp procedure was performed with a low dose insulin infusion (20 mU/m2/min) for 3 hours followed by a primed high dose insulin infusion (160 mU/m2/min x 5 minutes then 80 mU/m2/min) for two hours. D20 was infused and adjusted to maintain the blood glucose at 90 mg/dl. Samples for glucose, insulin and 6,6 2d glucose were drawn every 15 minutes during the final half hour of the basal, low dose and high dose insulin periods. Whole body insulin sensitivity was calculated as the rate of glucose disposal (Rd)/lean body mass during the high dose insulin infusion.</description>
          <population>One person in Arm 1 dropped out and thus is lacking 6 month data. The 6 month isotope data to calculate the rate of glucose disposal was not available for one subject in Arm 3.</population>
          <units>mg/min/kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="2.11"/>
                    <measurement group_id="O2" value="0.123" spread="2.62"/>
                    <measurement group_id="O3" value="-0.24" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Intra-abdominal Fat Area From Baseline to 6 Months</title>
        <description>Unenhanced CT scan images were obtained on a General Electric Discovery HD750 CT scanner. Intra-abdominal (IAF) areas were measured at the top of the iliac crest and quantified using the Tomovision program (SliceOMatic V4.3) by one trained technologist.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Intra-abdominal Fat Area From Baseline to 6 Months</title>
          <description>Unenhanced CT scan images were obtained on a General Electric Discovery HD750 CT scanner. Intra-abdominal (IAF) areas were measured at the top of the iliac crest and quantified using the Tomovision program (SliceOMatic V4.3) by one trained technologist.</description>
          <units>mm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="885" spread="874"/>
                    <measurement group_id="O2" value="440" spread="2788"/>
                    <measurement group_id="O3" value="108" spread="3416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hepatic Insulin Sensitivity From Baseline to 6 Months</title>
        <description>Hepatic insulin sensitivity was determined as the percent suppression of endogenous glucose production (EGP) at the end of the low dose insulin clamp.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hepatic Insulin Sensitivity From Baseline to 6 Months</title>
          <description>Hepatic insulin sensitivity was determined as the percent suppression of endogenous glucose production (EGP) at the end of the low dose insulin clamp.</description>
          <units>percent of baseline EGP</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="7.8"/>
                    <measurement group_id="O2" value="-4.09" spread="4.34"/>
                    <measurement group_id="O3" value="4.91" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>matching placebo for rosiglitazone, 1 po bid and placebo for fenofibrate 1 po qd</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>rosiglitazone 4 mg po bid and fenofibrate placebo 1 po qd</description>
        </group>
        <group group_id="E3">
          <title>Arm 3</title>
          <description>micronized fenofibrate 200 mg 1 po qd and rosiglitazone placebo 1 po bid</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leg edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>vasovagal reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>gout attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>increased serum Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to recruitment difficulties and concerns about the safety of thiazolidinediones, recruitment was stopped without achieving adequate sample size (16/arm). Thus, no definitive conclusions can be made about the study medications.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kristina Utzschneider, MD</name_or_title>
      <organization>VA Puget Sound Health Care System</organization>
      <phone>206-277-3568</phone>
      <email>kristina.utzschneider@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

